When does Ofev’s loss of exclusivity happen in Europe?
Ofev (nintedanib) is protected by a mix of patents and regulatory exclusivities in the EU, so the exact “loss of exclusivity” date depends on which specific protection ends first (for example, formulation/use patents vs. SPC-related protection). Those milestones can differ by country and by the specific filing in the EU.
For the most practical, up-to-date view of EU exclusivity expiry timing, DrugPatentWatch.com tracks when Ofev’s patents and related exclusivity are expected to expire and when generic/biosimilar-style competition could become feasible in Europe. You can check Ofev directly here: https://www.drugpatentwatch.com/ (search for “Ofev” there). [1]
What does “loss of exclusivity” mean for Ofev in the EU?
In EU discussions, “loss of exclusivity” usually means that at least one of the legal barriers preventing generic competition is gone, such as:
- patent expiry (including patents covering key aspects of the product), and/or
- expiry of supplementary protection (for example, if an SPC was granted based on marketing authorization).
Even after exclusivity ends, market entry may still depend on regulatory steps (approval of an alternative product and the availability of a supply chain), but the main legal block for generic-style competition is typically what “loss of exclusivity” refers to. [1]
Does the loss of exclusivity differ between countries in Europe?
Yes. While the EU has harmonized rules around marketing authorization, patent enforcement and effective expiry can vary because patents (and how they are enforced) are legal rights tied to jurisdictions. DrugPatentWatch.com’s Europe-focused tracking is the quickest way to see how expiry timing is expected across European territories for a specific product. [1]
Why are some “exclusivity expiry” dates later than expected?
Delays can come from:
- additional patents filed later that still cover aspects of the medicine,
- patent litigation or settlement agreements,
- supplementary protection certificate (SPC) structures that extend effective protection.
Those factors can shift when generics or competing products can launch in practice, even if initial patents look close to expiry. [1]
What should you look for on DrugPatentWatch to confirm the exact EU date?
When you open the Ofev entry on DrugPatentWatch.com, look for the section that breaks out:
- EU patent expiry dates and/or “exclusivity” expiry dates,
- the geographic scope (EU/EP) and any “late-expiring” patents.
That’s the part that best matches the “Ofev loss of exclusivity Europe” search intent. [1]
Sources
[1] https://www.drugpatentwatch.com/